Available Clinical Trials

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724). E-mail: askrpci@roswellpark.org
 

NRG-GU003: A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
Principal Investigator: Kuettel, Michael R
Race and geographic differences in diagnosis with metastatic Prostate cancer and early detection
Principal Investigator: Sumlin, Adam B
NRG-BR005: A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving...
Principal Investigator: Levine, Ellis G
2125-204, A Phase 1/2 Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination with Ipilimumab or Pembrolizumab in Patients with Metastatic Melanoma
Principal Investigator: Puzanov, Igor
DFCI ALL Consortium 16-001: Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Principal Investigator: Kelly, Kara M
Mindfulness Based Intervention for Cancer Caregivers
Principal Investigator: Bouchard, Elizabeth G
A Phase 1/2 dose escalation study with expansion cohorts to investigate the safety, biologic and anti-tumor activity of ONCOS-102 in combination with durvalumab in subjects with advanced peritoneal malignancies
Principal Investigator: Odunsi, Adekunle O
Life On The Go 2: Evaluating the Effect of Physical Activity of Patients with Recurrent Ovarian Cancer Using State of the Art Activity Tracking Device
Principal Investigator: Zsiros, Emese
(S1609) DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
Principal Investigator: Puzanov, Igor
A multicenter phase II study of pembrolizumab (MK-3475) in patients with advanced small bowel adenocarcinomas
Principal Investigator: Boland, Patrick M
A Phase Ib/2 Trial of Fludarabine/Melphalan/Total Body Irradiation with Post Transplant Cyclophosphamide as Graft versus Host Disease Prophylaxis in Matched-Related and Matched-Unrelated Allogeneic Hematopoietic Cell Transplantation
Principal Investigator: Ho, Christine M
"Talking Pictures": An exploratory study of meaning-based social media intervention for Adolescent and Young Adult cancer patients
Principal Investigator: Beaupin, Lynda K
A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)
Principal Investigator: Iyer, Renuka V
(RU021416I) BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab plus Atezolizumab versus Capecitabine Bevacizumab plus Placebo in Patients with Refractory Metastatic Colorectal Cancer
Principal Investigator: Boland, Patrick M
A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Principal Investigator: Mohler, James L
(MEDI4736-DLBCL-001) A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Clinical Activity of Durvalumab in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R CHOP) or with Lenalidomide plus R CHOP (R2...
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
(NRG-GU002) Phase II-III Trial Of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or without Adjuvant Docetaxel
Principal Investigator: Chatta, Gurkamal S
Phase 1/2a Study of BMS-986178 Administered Alone and in Combination with Nivolumab or Ipilimumab in Advanced Solid Tumors
Principal Investigator: Puzanov, Igor
Exercise to Improve Health and Quality-of-life in Breast Cancer Survivors
Principal Investigator: O'Connor, Tracey L
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-502 in Patients with Advanced Solid Tumors with HER2 Expression
Principal Investigator: Puzanov, Igor
A Phase 1, Open Label, Dose Escalation Study of MGA271 in Combination with Pembrolizumab in Patients with B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer and other B7-H3-Expressing...
Principal Investigator: Chatta, Gurkamal S
A Phase 1b Study of Intratumoral IMO 2125 in Patients with Refractory Solid Tumors (2125-RST-101)
Principal Investigator: Puzanov, Igor
(RTOG 1119) Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination with Concurrent Lapatinib in Patients with Brain Metastasis From HER2-Positive Breast Cancer - A Collaboartive Study of NRG Oncology and KROG
Principal Investigator: Prasad, Dheerendra
Direct oral anticoagulants (DOACs) versus LMWH +/- warfarin for VTE in cancer: A randomized effectiveness trial (CANVAS trial)
Principal Investigator: Levine, Ellis G
A Randomized Phase II Multicenter Open Label Study Evaluating Sirolimus and Prednisone in Patients with Refined Minnesota Standard Risk Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease
Principal Investigator: Chen, George L
(AAA-177Lu-03) Expanded access protocol for therapeutic use of 177Lu-DOTA0-Tyr3-Octreotate in patients with inoperable, somatostatin receptor positive, neuroendocrine tumors, progressive under somatostatin analogue therapy
Principal Investigator: Lamonica, Dominick
A Randomized, Open-label, Multicenter, Phase 3 Study To Evaluate The Efficacy And Safety Of Avelumab (MSB0010718C) In Combination With And/or Following Chemotherapy In Patients With Previously Untreated Epithelial Ovarian Cancer (JAVELIN Ovarian 100)
Principal Investigator: Lele, Shashikant B
Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women with Dense Breasts (EA1141)
Principal Investigator: Bonaccio, Ermelinda
A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency
Principal Investigator: Chatta, Gurkamal S
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC)
Principal Investigator: George, Saby
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR)
Principal Investigator: George, Saby
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers
Principal Investigator: George, Saby
Phase 2, randomized, open-label study comparing daratumumab, lenalidomide, bortezomib, and dexamethasone (D-RVd) versus lenalidomide, bortezomib, and dexamethasone (RVd) in subjects with newly diagnosed multiple myeloma eligible for high-dose...
Principal Investigator: Torka, Pallawi
(UPCI 15-131) Dose-seeking and Efficacy Study of Pembrolizumab plus Vemurafenib for Therapy of Advanced Melanoma
Principal Investigator: Ernstoff, Marc S
CA209204, A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects with Melanoma Metastatic to the Brain treated with Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy
Principal Investigator: Puzanov, Igor
A Multicenter Pivotal Phase 3 study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects with Active, Relapsed, or Refractory Acute Myeloid Leukemia
Principal Investigator: Chen, George L
An Open-Label Phase 1/2 Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
(CCT-PNK-007-MM-001) A phase 1, multicenter, open-label, safety study of human cord blood derived, culture-expanded, natural killer cell (PNK-007) infusion with subcutaneous recombinant human IL-2 (rhIL-2) following autologous stem cell transplant for...
Principal Investigator: Ho, Christine M
(SGI-110-06) A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia
Principal Investigator: Griffiths, Elizabeth A
A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion- Positive Tumors (LOXO-TRK-15002).
Principal Investigator: Grand'Maison, Anne C
A Randomized, Double-Blind, Placebo-Controlled Phase III study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone -Sensitive Prostate Cancer
Principal Investigator: George, Saby
A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma
Principal Investigator: Zsiros, Emese
MATCH Treatment Subprotocol Z1I: Phase II Study of AZD1775 in Patients with Tumors Containing BRCA1 and BRCA2 Mutations
Principal Investigator: Levine, Ellis G
MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
Principal Investigator: Levine, Ellis G
(A091202) A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients with Previously Treated, Unresectable Myxoid Liposarcoma
Principal Investigator: Grand'Maison, Anne C
A multicenter open-label treatment protocol of gilteritinib (ASP2215) in patients with FMS-like tyrosine kinase 3 (FLT3) mutated relapsed or refractory acute myeloid leukemia (AML) or FLT3 mutated AML in complete remission (CR) with minimal residual...
Principal Investigator: Wang, Eunice S
A Phase 2/3 Multicenter, Open-label, 3 arm, 2 stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not...
Principal Investigator: Wang, Eunice S
MATCH Treatment Subprotocol Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
Principal Investigator: Levine, Ellis G
(EAQ152): COMET - Communication and Education in Tumor Profiling:A Randomized Study of Pre-disclosure Genetic Education v Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential...
Principal Investigator: Levine, Ellis G
S1512) A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Primary Locally Advanced, Locally Recurrent or Metastatic Desmoplastic Melanoma (DM)
Principal Investigator: Ernstoff, Marc S
A PHASE 1 STUDY OF ES414 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Principal Investigator: Chatta, Gurkamal S
A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination with Azacitidine in Patients with Previously Untreated International Prognostic Scoring System (IPSS) Intermediate - 2 or High-Risk Myelodysplastic Syndrome (MDS)
Principal Investigator: Griffiths, Elizabeth A
S1418/BR006) A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 [Pembrolizumab] as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After...
Principal Investigator: Levine, Ellis G
( SCRX001-006) An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors
Principal Investigator: Dy, Grace K
Vigilant Observation of Gliadel Wafer Implant (VIGILANT) Registry: A multicenter, observational registry to collect information on the safety and effectiveness of Gliadel Wafer (Carmustine Implant) used in usual medical practice
Principal Investigator: Fabiano, Andrew J
MM-310-01-01-01: A Phase 1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients with Solid Tumors
Principal Investigator: Ernstoff, Marc S
An Open Label, Dose-Finding and Proof of Concept Study of the PD-L1 Probody Therapeutic, CX-072, as Monotherapy and in Combination with Yervoy® (Ipilimumab) or with Zelboraf® (Vemurafenib) in Subjects with Advanced or Recurrent Solid Tumors or...
Principal Investigator: Opyrchal, Mateusz
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)
Principal Investigator: Dy, Grace K
Study 16-214-02 (Combination): A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies
Principal Investigator: Puzanov, Igor
(A011502): A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
Principal Investigator: Levine, Ellis G
(EDDOP IL 057/ NCI 9706) RANDOMIZED PHASE II STUDY TO ASSESS THE ROLE OF NIVOLUMAB AS SINGLE AGENT TO ELIMINATE MINIMAL RESIDUAL DISEASE AND MAINTAIN REMISSION IN ACUTE MYELOGENOUS LEUKEMIA (AML) PATIENTS AFTER CHEMOTHERAPY (REMAIN TRIAL)
Principal Investigator: Griffiths, Elizabeth A
Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 in Metastatic Pancreatic Cancer
Principal Investigator: Fountzilas, Christos
(COG ANHL12P1) A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC# 749005, Commerically Labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND# 117117
Principal Investigator: Barth, Matthew J
(COG AOST1321) Phase 2 Study of Denosumab (IND#127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma
Principal Investigator: Twist, Clare J
Randomized phase IB/II study of enzalutamide with and without ribociclib in patients with metastatic castrate resistant, chemotherapy naïve prostate cancer that retains RB expression
Principal Investigator: Chatta, Gurkamal S
A051301/BMT CTN 1201; A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Principal Investigator: McCarthy, Philip L
(COG AAML1531) Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Principal Investigator: Twist, Clare J
A multinational, open-label, dose escalation Phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumor types
Principal Investigator: Odunsi, Adekunle O
A Phase I, MultiCenter, Open-Label, Dose-Escalating, Safety Study of Human Cord Blood Derived, Culture Expanded, Natural Killer Cell (PNK-007) Infusion with Subcutaneous Recombinant Human IL-2 (RHIL-2) In Adults with Relapse and/or Refractory Acute...
Principal Investigator: Wang, Eunice S
A Phase 1 Dose-Escalation and Cohort-Expansion Study of Intravenous CBL0137 in Subjects with Previously Treated Hematological Cancers
Principal Investigator: Bhat, Seema A
NRG-GYN 005 A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or...
Principal Investigator: Lele, Shashikant B
A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly...
Principal Investigator: Griffiths, Elizabeth A
A Randomized Multicenter Phase II Study Using (2-1[Heyloxyethyl]-2-Devinylpyropheophorbide-a) (HPPH) with PDT versus Standard of Care Surgery for Patients with T1/T2 N0 Squamous Cell Carcinoma of the Oral Cavity
Principal Investigator: Arshad, Hassan
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents
Principal Investigator: Griffiths, Elizabeth A
A Phase II Evaluation of Copanlisib (BAY 80-6946) (IND #130822), A Selective Inhibitor of PI3KCA, in Patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
Principal Investigator: Lele, Shashikant B
S1416, Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
Principal Investigator: Levine, Ellis G
An Intensive QT/QTc Study to Investigate the Effects of Rovalpituzumab Tesirine on Cardiac Ventricular Repolarization in Subjects with Small Cell Lung Cancer
Principal Investigator: Dy, Grace K
NCI 9855; A Phase 2 Study of CDX-011 (glembatumumab vedotin) for Metastatic Uveal Melanoma
Principal Investigator: Opyrchal, Mateusz
A011401; Randomized Phase III Trial Evaluating The Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Principal Investigator: O'Connor, Tracey L
A221208; Randomized Phase II Study: Corticosteroids + Bevacizumab VS. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Principal Investigator: Prasad, Dheerendra
Phase 1/2 Dose-Escalation, Safety, Clinical Activity, Pharmacokinetic and Pharmacodynamic Study of the ERK1/2 Inhibitor BVD-523 in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndromes
Principal Investigator: Wang, Eunice S
A Multicenter Phase I/II Study Of Enzalutamide With And Without Sorafenib In Advanced Hepatocellular Carcinoma Patients
Principal Investigator: Iyer, Renuka V
NRG-GY004: A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Principal Investigator: Lele, Shashikant B
(CITN-12) Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Principal Investigator: Ernstoff, Marc S
A Phase II Study of Enzalutamide(NSC# 766085) for Patients with Androgen Receptor Positive Salivary Glands
Principal Investigator: Chen, Hongbin
MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
Principal Investigator: Levine, Ellis G
MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification-SUSPENDED
Principal Investigator: Levine, Ellis G
MATCH Treatment Subprotocol Z1D: Nivolumab in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer)
Principal Investigator: Levine, Ellis G
MATCH Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification and Rb Protein Expression by IHC
Principal Investigator: Levine, Ellis G
MATCH Treatment Subprotocol Z1A: Binimetinib in Patients with Tumors (Other Than Melanoma) with NRAS Mutations
Principal Investigator: Levine, Ellis G
A Phase I/II Study of the EGF Vaccine CIMAvax in Combination with the Anti-PD1 Nivolumab in Patients with Previously Treated Advanced NSCLC
Principal Investigator: Dy, Grace K
Double-arm, Randomized Study of Botulinum Toxin Injection as a Pyloric Drainage Procedure for Minimally Invasive Esophagectomy (Phase II)
Principal Investigator: Kukar, Moshim
MATCH Treatment Subprotocol W: Phase II Study of AZD4547 in Patients with Tumors with Aberrations in the FGFR Pathway
Principal Investigator: Levine, Ellis G
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma
Principal Investigator: Puzanov, Igor
A Phase I Evaluation of Olaparib in combination with Durvalumab and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients who Carry a...
Principal Investigator: Odunsi, Adekunle O
A Phase I/II Open-Label Study of Nimotuzumab in Combination with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer
Principal Investigator: Dy, Grace K
(EA3132) Phase II Randomized Trial of Adjuvant Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing
Principal Investigator: Chen, Hongbin
A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors
Principal Investigator: Ernstoff, Marc S
A Multi-center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Principal Investigator: George, Saby
A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma
Principal Investigator: Chatta, Gurkamal S
(EA5142) Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Principal Investigator: Dy, Grace K
A Phase 1, Multi-Center, Open-Label Study of IMGN779 Administered Intravenously in Adult Patients with Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia
Principal Investigator: Wang, Eunice S
A Phase I Study of Donor BPX-501 T Cell Infusion for Adults with Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogenetic Transplant
Principal Investigator: Chen, George L
A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
Principal Investigator: Boland, Patrick M
A Phase I/II Open-Label, Dose Escalation, Safety and Activity Study of the Antibody-Drug Conjugate CDX-014 in Advanced or Metastatic Renal Cell Carcinoma (RCC)
Principal Investigator: George, Saby
(A-US-52030-328) A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Auto/Gel Depot 120 mg Plus BSC Vs. Placebo Plus BSC for Tumor Control in Subjects with Well Differentiated, Metastatic And...
Principal Investigator: Chen, Hongbin
(COG ALTE1621) Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial
Principal Investigator: Rokitka, Denise A
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies
Principal Investigator: Wang, Eunice S
(SWOG 1404) A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma
Principal Investigator: Ernstoff, Marc S
(EAY 131-X MATCH): Phase II Study of Dasatinib in Patients with Tumors with DDR2 Mutations
Principal Investigator: Levine, Ellis G
(EAY 131-V MATCH): Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
Principal Investigator: Levine, Ellis G
(EAY 131-U MATCH): VS-6063 (defactinib) in Patients with Tumors with NF2 Loss
Principal Investigator: Levine, Ellis G
(EAY 131-T MATCH): GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
Principal Investigator: Levine, Ellis G
EAY 131-S2 MATCH): Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations
Principal Investigator: Levine, Ellis G
(EAY 131-S1 MATCH): Phase II Study of Trametinib in Patients with Tumors with NF1 mutations
Principal Investigator: Levine, Ellis G
(EAY 131-N MATCH): Phase II Study of PI3K Beta Specific Inhibitor, GSK2636771, in Patients with Tumors with PTEN Mutation or Deletion, with PTEN Expression on IHC
Principal Investigator: Levine, Ellis G
(EAY 131-I MATCH): GDC-0032 (taselisib) in Patients with Tumors (other than breast cancer) with PIK3CA Mutation but without KRAS Mutation or PTEN Loss
Principal Investigator: Levine, Ellis G
(EAY 131-B MATCH): Phase II Study of Afatinib in Patients with Tumors with HER2 Activating Mutations
Principal Investigator: Levine, Ellis G
(EAY 131-E MATCH): AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
Principal Investigator: Levine, Ellis G
(EAY 131-H MATCH): Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma and Thyroid Cancer)
Principal Investigator: Levine, Ellis G
(EAY 131-G MATCH): Phase II Study of Crizotinib in Patients with ROS1 Translocations (Other Than Patients with Non-Small Cell Lung Cancer)
Principal Investigator: Levine, Ellis G
(EAY 131-F MATCH): Crizotinib in Patients with Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Translocations
Principal Investigator: Levine, Ellis G
A Phase III Study of Lenalidomide and Low-Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Newly Diagnosed and Treatment Naive Multiple Myeloma (KEYNOTE 185)
Principal Investigator: Lee, Kelvin
(EAY 131-A MATCH): Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
Principal Investigator: Levine, Ellis G
Phase Ib Trial of Pembrolizumab (MK-3475) in Combination with Dinaciclib (MK-7965) in Subjects with Hematologic Malignancies (KEYNOTE-155)
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
(EAY 131 Master Protocol) Molecular Analysis for Therapy Choice (MATCH)
Principal Investigator: Levine, Ellis G
Phase 0 Trial of Presurgical Cholesterol-lowering on Prostate Cancer Cell Growth
Principal Investigator: Mohler, James L
(BMT CTN Protocol 1401) Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccinations with Dendritic Cell/Myeloma Fusions
Principal Investigator: Torka, Pallawi
A Phase 1a/1b Study of Cabiralizumab in Combination with Nivolumab in Patients with Selected Advanced Cancers
Principal Investigator: Opyrchal, Mateusz
(COG AAML1522/CC-5013-AML-002) A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (Revlimid®) in Pediatric Subjects from 1 to = 18 Years of Age with Relapsed or Refractory...
Principal Investigator: Twist, Clare J
A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer
Principal Investigator: George, Saby
(A061402) Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid after Definite Radiation Therapy
Principal Investigator: Lee, Kelvin
A Phase II Evaluation of Pembrolizumab in Combination with IV Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Principal Investigator: Zsiros, Emese
A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
Principal Investigator: Lee, Kelvin
A Phase 3, Multicenter, Open-Label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation
Principal Investigator: Wang, Eunice S
(EA1131) A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Principal Investigator: Levine, Ellis G
Single-Arm, Non-Inferiority Study of Omission of Intraoperative Intact Parathyroid Hormone (PTH) during Minimally Invasive Parathyroidectomy for Primary Hyperparathyroidism
Principal Investigator: Kukar, Moshim
A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (nal-IRI)-containing Regimens versus nab-Paclitaxel plus Gemcitabine in Patients with Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Principal Investigator: Boland, Patrick M
(COG APEC14B1) The Project: Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Principal Investigator: Bambach, Barbara J
A Phase Ib/II Study of Cetuximab and Pembrolizumab in Metastatic Colorectal Cancer
Principal Investigator: Boland, Patrick M
(BMT CTN 1302) Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma
Principal Investigator: McCarthy, Philip L
PALLAS: PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor...
Principal Investigator: Levine, Ellis G
(12-100) Phase I/II Trial of Pre-Operative Image Guided Intensity Modulated Proton Radiation Therapy (IMPT) or Photon (IMRT) with Simutaneously Integrated Boost to the High Risk Margin for Retroperitoneal Sarcomas
Principal Investigator: Salerno, Kilian E
(A031102) A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Pacilitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide ...
Principal Investigator: Levine, Ellis G
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Principal Investigator: Levine, Ellis G
(S1314) A Randomized Phase II Study Of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Principal Investigator: Levine, Ellis G
A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Activity of Oraxol in Subjects with Advanced Malignancies
Principal Investigator: Boland, Patrick M
Nicotine Delivery From Novel Non-Tobacco Electronic Systems (ENDS)
Principal Investigator: Mahoney, Martin C
(ACCL1333/CV185-155) A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly...
Principal Investigator: Bambach, Barbara J
A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6 Mercaptopurine) for Patients > or = 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and...
Principal Investigator: Wang, Eunice S
(2215-CL-0301) A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation
Principal Investigator: Wang, Eunice S
(COG AAML1331) A Phase III Study For Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
Principal Investigator: Bambach, Barbara J
A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-small Cell Lung Cancer, with Expansion Cohorts in Patients with Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair-Proficient...
Principal Investigator: Opyrchal, Mateusz
(COG AALL1331) Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC# 765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Principal Investigator: Bambach, Barbara J
A Phase II, Multicenter, Study of Oral cMET Inhibitor INC280 in Adult Patients with EGFR Wild-Type (wt), Advanced Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator: Chen, Hongbin
GOG 0286B) A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo As Initial Therapy For Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Principal Investigator: Lele, Shashikant B
(ASTX727-01) A Phase 1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)
Principal Investigator: Griffiths, Elizabeth A
(BMT CTN Protocol 0702) Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients Who Have Enrolled on BMT CTN 0702
Principal Investigator: McCarthy, Philip L
(COG ANBL1232) Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma
Principal Investigator: Higman, Meghan
(COG AHOD1331) A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Principal Investigator: Higman, Meghan
SL-401 in Patients with Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
Principal Investigator: Wang, Eunice S
A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma
Principal Investigator: Fenstermaker, Robert A
(PBMTC 13-TLEC) Natural History and Biology of Long-Term Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Principal Investigator: Bambach, Barbara J
(S1400) A Biomarker-Driven Master Protocol for Previously treated Squamous Cell Lung Cancer (Lung-Map)
Principal Investigator: Chen, Hongbin
Multicenter Phase II Study of Nintedanib for Patients with Advanced Carcinoid Tumors
Principal Investigator: Iyer, Renuka V
Phase II Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis against Radiation Pneumonitis in Patients with Unresectable NSCLC Undergoing Chemoradiation Therapy
Principal Investigator: Dy, Grace K
Analysis of Analgesia Regimens during Concurrent Chemoradiation for Head and Neck Cancer: A Pilot Study
Principal Investigator: Singh, Anurag K
(C31001) A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment...
Principal Investigator: Opyrchal, Mateusz
(E4512 )A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Principal Investigator: Chen, Hongbin
(A081105) Randomized Study of Erlotinib or Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator: Dy, Grace K
(A151216) Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Principal Investigator: Dy, Grace K
(COG ALTE11C1) Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma
Principal Investigator: Rokitka, Denise A
(NRG/COG ARST1321) Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)
Principal Investigator: Salerno, Kilian E
(BMT CTN 1102) A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic...
Principal Investigator: McCarthy, Philip L
Phase I Study of Oral PQR309 in Patients with Advanced Solid Tumors
Principal Investigator: Opyrchal, Mateusz
(COG AALL1231) A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphobalstic Lymphoma (T-LLy)
Principal Investigator: Bambach, Barbara J
(E2112) A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer
Principal Investigator: Levine, Ellis G
A Phase I/IIa Study of TGFß Blockade in TCR-Engineered T-Cell Cancer Immunotherapy in Patients with Advanced Malignancies
Principal Investigator: Odunsi, Adekunle O
(E1910) A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Principal Investigator: Wang, Eunice S
A Dose-Regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects with Advanced Malignancies
Principal Investigator: Boland, Patrick M
(UPCC 14153) A Randomized Phase II Trial of Radical Pleurectomy and Post-Operative Chemotherapy With or Without Intraoperative Porfimer Sodium-Mediated Photodynamic Therapy for Patients with Epithelioid Malignant Pleural Mesothelioma
Principal Investigator: Yendamuri, Sai S
A Phase I Study of Ceritinib (LDK378), a Novel ALK Inhibitor, in Combination with Gemcitabine-Based Chemotherapy in Patients with Advanced Solid Tumors
Principal Investigator: Iyer, Renuka V
(BP-HM-001) A Phase 1-2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells after Partially Mismatched, Related T Cell-Depleted HSCT
Principal Investigator: Chen, George L
(MISP50442) An Observational Pilot Study to Compare the Compliance with and Health Related Quality of Life during Therapy with Standard High-Dose Interferon Alfa (Intron® A, HDI) versus Pegylated Alfa-Interferon 2b (Sylatron, PEG IFN) in Patients...
Principal Investigator: Ernstoff, Marc S
(BAY 1129980/16044) An Open-Label Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Pharmacodynamics of the Anti-C4.4a Antibody Drug Conjugate BAY 1129980 in Subjects With Advanced Solid...
Principal Investigator: Opyrchal, Mateusz
(KX02-01-13) A Phase 1 Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KX2-361 in Subjects with Advanced Malignancies that are Refractory to Conventional Therapies
Principal Investigator: Opyrchal, Mateusz
(BMT CTN 1204) Reduced-Intensity Conditioning for Children and Adults with Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (RICHI)
Principal Investigator: Bambach, Barbara J
(A011202) A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 NI) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Principal Investigator: Levine, Ellis G
(Alliance A011106) ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Principal Investigator: Levine, Ellis G
(COG ALTE11C2) Health Effects After Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy
Principal Investigator: Rokitka, Denise A
Reduced Burden of Oncologic Therapy in Advanced B-cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults with CD20+ Mature B-Cell Lymphoma
Principal Investigator: Barth, Matthew J
Phase I/II Study of Carfilzomib plus Rituximab plus Ifosfamide plus Carboplatin plus Etoposide (C-R-ICE) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
N1048 PROSPECT**) A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiaiton Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with...
Principal Investigator: Nurkin, Steven J
(1137-101) A Phase I Trial of CBL0137 in Patients with Advanced Solid Neoplasms
Principal Investigator: Iyer, Renuka V
(COG ANBL1221) A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma
Principal Investigator: Twist, Clare J
A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) with Temoporfin in Patients with Resectable Primary Non-Small Cell Lung Cancer (NSCLC) with Ipsilateral Thoracic Nodal (N1 or N2) or T3/T4 Disease
Principal Investigator: Nwogu, Chukwumere E
Pilot: Impact of High-Dose, Single Fraction Radiation on Immunogenicity of Sipuleucel-T in Metastatic Castration Recurrent Prostate Cancer Patients
Principal Investigator: Chatta, Gurkamal S
A Phase I Trial of a Recombinant Human hsp110-gp100 Chaperone Complex Vaccine for Advanced Stage IIIB/C or IV Melanoma
Principal Investigator: Kane, John M
Impact of Carbonyl Reductase 3 Genotype Status on Echocardiographic Measurements of Cardiomyopathy in Breast Cancer Patients Treated with Anthracyclines
Principal Investigator: O'Connor, Tracey L
A Pilot Study of Broccoli Sprout Extract in Patients with Breast Cancer
Principal Investigator: Young, Jessica S
A Phase I/ II Trial of Pazopanib Alternating with Bevacizumab in Treatment-Naive Metastatic Clear Cell Renal Cell Carcinoma Patients
Principal Investigator: George, Saby
Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry
Principal Investigator: Griffiths, Elizabeth A
COG AALL1131, A Phase III Randomized Trial for Newly Diagnosed High Risk BLymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Principal Investigator: Bambach, Barbara J
(COG ANHL04B1) Rare and Cutaneous Non-Hodgkin Lymphoma Registry
Principal Investigator: Barth, Matthew J
A Pilot Study Evaluating NFAT, NFkB and, ERK 1/2 Nuclear Translocation as a Predictive Marker for Acute Graft-versus-Host Disease
Principal Investigator: Chen, George L
(CIBMTR 10-CBA) A Multicenter Access and Distribution Protocol for Unlicensed Cryopreseved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
Principal Investigator: McCarthy, Philip L
Ofatumumab (O) in Combination With Chemotherapy: Hyper-Fractionated Cyclophosphamide, Doxorubicin, Vincristine and Dexamethasone (O-HyperCVAD) Alternating With Ofatumumab High-Dose Cytarabine and Methotrexate (O-MA) for Patients With Newly Diagnosed...
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
Examining Quality of Life Among Long-Term Survivors of Childhood Cancer
Principal Investigator: Rokitka, Denise A
Mediators of inflammation and injury in patients receiving cancer therapy or allogeneic hematopoietic stem cell transplantation
Principal Investigator: Segal, Brahm
(COG ACNS0831) Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years
Principal Investigator: Twist, Clare J
(COG AALL0932) Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)
Principal Investigator: Bambach, Barbara J
(COG AALL08B1) Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Principal Investigator: Twist, Clare J
Lung Bronchoscopy Research Samples & Database
Principal Investigator: Hennon, Mark W
Leukocyte Apheresis for Research
Principal Investigator: Odunsi, Adekunle O
(COG ALTE03N1) Key Adverse Events After Childhood Cancer
Principal Investigator: Rokitka, Denise A
Evaluation and Quality Assurance of the New York State Smokers' Quitline
Principal Investigator: Hyland, Andrew J
Novel Risk Factors and Potential Early Detection Markers for Ovarian Cancer
Principal Investigator: Moysich, Kirsten B
Collection of Blood from Healthy Donors and Patients with Non-Hodgkin's Lymphoma and Leukemia to Study the Immunological Activity of Peripheral Blood Mononuclear Cells (PBMC) and Human Serum
Principal Investigator: Hernandez-Ilizaliturri, Francisco J
(COG AALL05B1) A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
Principal Investigator: Twist, Clare J
Evaluation of Smoker Reactions to Novel Tobacco Products
Principal Investigator: Bansal Travers, Maansi
(COG ACNS0332) Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Principal Investigator: Fitzpatrick, Lorna
Randomized Placebo-Controlled, Double-Blind Study Of Cholecalciferol Replacement in Patients on Expectant Management for Localized Prostate Cancer
Principal Investigator: Mohler, James L
Intensity Modulated Radiation Therapy for Anal Cancer: Dosimetric Comparison, Acute Toxicity Profile, and Quality of Life Assessment
Principal Investigator: Mattson, David
(COG ALTE05N1) Umbrella Long-Term Follow-Up Protocol
Principal Investigator: Rokitka, Denise A
Assessment of Tumor Cell Viability and Various Biomarkers from De-Identified Bladder Washing Samples Obtained From Patients with Bladder Carcinoma
Principal Investigator: Guru, Khurshid
Brody Belt
Principal Investigator: Guru, Khurshid
(COG AHEP0731) Treatment of Children with All Stages of Hepatoblastoma
Principal Investigator: Rokitka, Denise A
Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation with Unrelated Donors (NMDP IRB 1996-005; IRB-1999-0021)
Principal Investigator: McCarthy, Philip L
Genetic Signature for Progression of Barrett's Esophagus to Esophageal Adenocarcinoma. A Pilot Study
Principal Investigator: Bain, Andrew J